JUNE 6: VIR Biotechnology: Favorable Barron's Article.

VIR got a favorable article in Barron's today. Its antibody approach is unique (along with SRNE) among the vaccine stocks. They have a robust history with this platform and hopefully can make it work. They have an arrangement with Biogen to get it manufactured. We may well see a nice pop early next week.

https://www.barrons.com/articles/antibody-drugs-could-help-curb-the-pandemic-what-investors-need-to-know-51591377732?mod=past_editions.  

https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-and-biogen-execute-agreement-manufacture-sars.

VIR started 2020 at $12.04 and closed yesterday at $33.21 but it has not been a really rock star among the COVID VACCINE stocks. It has the sixth largest market cap of the group.

Sorrento (SRNE) is another of the 24 that is in the antibody hunt: 

https://www.investors.com/news/technology/coronavirus-treatment-abbv-stock-rises-collaboration-covid-19/